Diakonos Oncology
Houston
About Diakonos Oncology
Diakonos Oncology focuses on developing dendritic cell vaccines to treat challenging cancer types, particularly glioblastoma. The company is in the clinical stage of its research, aiming to enhance cancer treatment through innovative immunotherapy approaches. Diakonos Oncology's lead product, DOC1021, is currently undergoing Phase II trials after receiving FDA Fast Track designation. The company actively presents its clinical findings at major medical conferences, showcasing the potential of its therapies to improve patient outcomes. Through its research efforts, Diakonos Oncology contributes to the advancement of cancer treatment options in the biotech field.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $38.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Dec 2025)
- Website: diakonosoncology.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/diakonos-oncology-77993 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.